T 0752/17 (Immunotherapy/ALNYLAM) of 24.03.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T075217.20210324
- Date of decision
- 24 March 2021
- Case number
- T 0752/17
- Petition for review of
- -
- Application number
- 05853546.9
- IPC class
- A61K 31/7088C07H 21/04C12N 15/11
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
- Applicant name
- Alnylam Pharmaceuticals Inc.
Hartmann, Gunther
Hornung, Veit
Endres, Stefan - Opponent name
- CABINET MALEMONT
- Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(a)European Patent Convention Art 100(b)European Patent Convention Art 100(c)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 87Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Added matter - (no)
Sufficiency of disclosure - (yes)
Priority - (yes)
Admission of new evidence - (no)
Novelty - (yes)
Inventive step - (yes) - Catchword
- -
- Cited cases
- G 0003/14T 0292/85T 0019/90T 0024/91T 0241/95T 0158/96T 0636/97T 1045/98T 1001/01T 1811/13T 1959/15
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.